IndieBio

Laguna Bio provides a drug discovery platform designed that activates and expands the innate immune system against cancer. It focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of a bispecific antibody drug. Laguna Biotherapeutics was founded in 2022 and is headquartered in Berkeley, California.

FREZENT is a biotechnology company that develops novel therapeutics for advanced-stage cancer patients.

Developing increasingly challenging vaccine targets requires increasingly sophisticated technologies. Over the last century, vaccines have made essential contributions to the doubling of human life expectancy. Calder engineers next-generation vaccines that will further protect against the most intractable and life-threatening viruses. Viruses have evolved to become shapeshifters that can evade and distract our immune system by hiding some of their most vulnerable sites. History has shown that pandemics are not only lethal but also inevitable. Currently, the vaccines we know best poorly protect against pandemics and other viral outbreaks and leave many at-risk populations unprotected. By combining structure-based design as part of a novel manufacturing process, Calder’s unique 3D-Vaxlock technology generates molecular staples that lock vaccines into their most potent shape. Their initial focus is on generating a universal flu vaccine that protects against all seasonal strains and an RSV vaccine specifically for the elderly. With this platform, they have the ability to create treatments that better protect against life-threatening diseases with exceptional safety, efficacy, and durability. Calder’s next generation vaccines will prevent severe disease and deaths, alleviate a substantial burden on the healthcare system, and allow billions of people to lead healthy lives.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Aluna is focused on empowering patients with chronic respiratory conditions, particularly asthma, by providing tools for better understanding and management of their lung health. The company has developed a portable spirometer device that utilizes machine learning and integrates with a mobile app. This technology allows patients to take daily measurements of their asthma, track symptoms, medication use, exercise, and environmental factors. By objectively monitoring asthma severity, the device enables healthcare providers to detect early signs of asthma attacks and create personalized, real-time action plans for their patients. Aluna is committed to enhancing the quality of life for individuals with asthma through innovative medical devices and healthcare solutions.

BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.

Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Laguna Bio provides a drug discovery platform designed that activates and expands the innate immune system against cancer. It focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of a bispecific antibody drug. Laguna Biotherapeutics was founded in 2022 and is headquartered in Berkeley, California.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Conan MedTech develops a rapid POC diagnostic test for concussions. The company aims to revolutionize the mild traumatic brain injury diagnosis market to allow sport medicine doctors and athletic coaches and trainers to make a decision on the sideline during a game. Conan MedTech was founded in 2020 and is based in Ithaca, New York.

Conan MedTech develops a rapid POC diagnostic test for concussions. The company aims to revolutionize the mild traumatic brain injury diagnosis market to allow sport medicine doctors and athletic coaches and trainers to make a decision on the sideline during a game. Conan MedTech was founded in 2020 and is based in Ithaca, New York.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can inhibit or promote ferroptosis, a form of regulated cell death. By targeting this process, Prothegen seeks to provide effective therapeutic options for patients, enhancing the treatment of conditions associated with uncontrolled cell death.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Dalton Bioanalytics is a developer of analytical technology that unlocks access to the wealth of information available in the blood. It resolves the inefficiency and expense that plagues traditional laboratory testing by digitizing the biochemical composition of blood and translating that digital signature into a comprehensive array of actionable health insights. The analytical technology deciphers the biochemical signature of blood to build narratives about internal biology. Dalton was headquartered in Los Angeles, California in 2019.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Aluna is focused on empowering patients with chronic respiratory conditions, particularly asthma, by providing tools for better understanding and management of their lung health. The company has developed a portable spirometer device that utilizes machine learning and integrates with a mobile app. This technology allows patients to take daily measurements of their asthma, track symptoms, medication use, exercise, and environmental factors. By objectively monitoring asthma severity, the device enables healthcare providers to detect early signs of asthma attacks and create personalized, real-time action plans for their patients. Aluna is committed to enhancing the quality of life for individuals with asthma through innovative medical devices and healthcare solutions.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Brightcure is solving the lack of treatment options available for patients suffering from recurrent urinary tract infections (UTIs). UTIs are one of world’s most common infections, affecting 50% of women and 12% of men worldwide. Current UTI treatments are not effective, can cause serious side effects, and often accelerate antibiotic-resistant infections. Total UTI costs currently amount over $ 8.6B per year. With UTI bacteria becoming increasingly difficult to treat, the size of the UTI market is expected to reach $ 12.41B by 2025. Brightcure utilizes the natural microbiome to reduce harmful bacteria and replenish the good bacteria in the vaginal flora. Brightcure’s bioactive intimate cream boosts the natural immune system to promote a healthy urinary tract. BrightCure was founded in 2019 and is headquartered in London, England. In 2020, BrightCure got a seed investment from SOSV and was selected as 1 out of 9 companies to be part of the world's largest biotech accelerator, Indiebio, to develop its first product. BrightCure has been selected as one of the Top 7 companies of the McKinsey Venture Challenge, Top 5 of the Mayor of London Competition, has won Imperial College's White City Innovation Program, and has taken part in the finals of ‘The Pitch’ London Competition being selected among 850 other applications.

Brightcure is solving the lack of treatment options available for patients suffering from recurrent urinary tract infections (UTIs). UTIs are one of world’s most common infections, affecting 50% of women and 12% of men worldwide. Current UTI treatments are not effective, can cause serious side effects, and often accelerate antibiotic-resistant infections. Total UTI costs currently amount over $ 8.6B per year. With UTI bacteria becoming increasingly difficult to treat, the size of the UTI market is expected to reach $ 12.41B by 2025. Brightcure utilizes the natural microbiome to reduce harmful bacteria and replenish the good bacteria in the vaginal flora. Brightcure’s bioactive intimate cream boosts the natural immune system to promote a healthy urinary tract. BrightCure was founded in 2019 and is headquartered in London, England. In 2020, BrightCure got a seed investment from SOSV and was selected as 1 out of 9 companies to be part of the world's largest biotech accelerator, Indiebio, to develop its first product. BrightCure has been selected as one of the Top 7 companies of the McKinsey Venture Challenge, Top 5 of the Mayor of London Competition, has won Imperial College's White City Innovation Program, and has taken part in the finals of ‘The Pitch’ London Competition being selected among 850 other applications.

Advanced Microbubbles Inc specializes in developing microbubbles as ultrasound contrast agents for targeted drug delivery, particularly in overcoming significant biological barriers like the blood-brain barrier and tumor endothelium. Founded in 2020 and based in Newark, California, the company offers a range of products including size-isolated microbubbles, polydisperse microbubbles, and biotin- or streptavidin-tagged variants. These microbubbles are agitated with ultrasound at the tumor site, facilitating the local delivery of drugs by temporarily opening barriers that typically hinder treatment. By enabling more effective drug delivery, Advanced Microbubbles aims to reduce side effects and improve survival outcomes for patients with various neurological conditions and cancer.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Dalton Bioanalytics is a developer of analytical technology that unlocks access to the wealth of information available in the blood. It resolves the inefficiency and expense that plagues traditional laboratory testing by digitizing the biochemical composition of blood and translating that digital signature into a comprehensive array of actionable health insights. The analytical technology deciphers the biochemical signature of blood to build narratives about internal biology. Dalton was headquartered in Los Angeles, California in 2019.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

CASPR Biotech, founded in 2018 and located in San Francisco, California, specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company creates portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits aim to provide healthcare professionals with a simple, rapid, and cost-effective solution for molecular detection, enhancing the accuracy and efficiency of clinical diagnostics.

CASPR Biotech, founded in 2018 and located in San Francisco, California, specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company creates portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits aim to provide healthcare professionals with a simple, rapid, and cost-effective solution for molecular detection, enhancing the accuracy and efficiency of clinical diagnostics.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Dalton Bioanalytics is a developer of analytical technology that unlocks access to the wealth of information available in the blood. It resolves the inefficiency and expense that plagues traditional laboratory testing by digitizing the biochemical composition of blood and translating that digital signature into a comprehensive array of actionable health insights. The analytical technology deciphers the biochemical signature of blood to build narratives about internal biology. Dalton was headquartered in Los Angeles, California in 2019.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Antibiotic Adjuvant, Inc. is a healthcare technology company based in Gainesville, Florida, founded in 2014. It specializes in developing decision support software aimed at improving antibiotic usage within healthcare facilities. The company's flagship product, SmartSteward, is designed to monitor and reduce infections and antibiotic resistance. It provides a suite of tools and educational resources tailored for healthcare administrators, physicians, and nurses. Administrators benefit from tools that optimize antibiotic use in real-time, while doctors receive pertinent information for effective prescribing. Nurses are equipped with surveillance tools for infection reporting and diagnosis. This innovative system addresses the complexities of antibiotic prescriptions in hospitals, aiming to enhance precision medicine for infectious diseases and promote automated resistance control.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Beeline is an early-stage preclinical cell therapy company developing the next generation of immune cell therapies for immune-mediated human disease, particularly diseases which result from the patient's own immune cells attacking healthy tissue. We are genetically engineering a patient's own immune cells to secrete therapeutic proteins in vivo and induce tolerance. In particular, we are re-engineering Regulatory T cells (Tregs) to produce optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins, and combining enhanced Treg function with antigen specificity via targeting receptors for improved localization.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

CASPR Biotech, founded in 2018 and located in San Francisco, California, specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company creates portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits aim to provide healthcare professionals with a simple, rapid, and cost-effective solution for molecular detection, enhancing the accuracy and efficiency of clinical diagnostics.

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Guided Clarity, Inc. is a biotechnology company based in San Francisco, California, established in 2018. The company specializes in the development and manufacturing of bioactive peptides aimed at promoting mitochondrial health, particularly for the aging population. Its product line includes medical foods that isolate specific bioactive proteins known for their potential to renew mitochondrial function. Guided Clarity is focused on addressing the health needs associated with aging through innovative nutritional solutions.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

NeuroQore, Inc. is a company based in Ottawa, Canada, specializing in the development of a monophasic repetitive transcranial magnetic stimulation system aimed at treating treatment-resistant depression. Founded in 2012, NeuroQore focuses on creating innovative neuromodulation treatments for various neurobehavioral conditions, including major depressive disorder and suicidality. The company collaborates with leading universities and research clinics to advance its research and therapeutic solutions. Its technology features a semiconductor switch that generates a unique magnetic pulse, designed to help patients improve their quality of life by addressing these challenging disorders.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Convalesce Inc. is a therapeutic company based in San Francisco, California, focused on developing stem cell-based therapies for neurodegenerative conditions, particularly Parkinson's disease. Founded in 2018, Convalesce utilizes advanced biomaterials to enhance the efficacy of stem cell treatments. Their innovative implantable biomaterials aim to improve stem cell survival and facilitate the differentiation of these cells into neurons after implantation. By addressing critical challenges in stem cell therapy, Convalesce seeks to enable healthcare professionals to regenerate neuronal networks lost due to degeneration, ultimately offering new hope for patients suffering from debilitating neurological disorders.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Osiris Bio

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Vetherapy is a biotech company established in 2015, specializing in veterinary regenerative medicine and tissue engineering. The company develops innovative products utilizing stem cells, platelet-rich plasma (PRP), and biomaterials to address various animal health conditions. Vetherapy focuses on ensuring quality and safety in the processes of stem cell isolation, expansion, and cryopreservation, as well as in the extraction of plasma rich in growth factors. By providing access to a stem cell and PRP bank through their cryopreservation services, Vetherapy ensures that these vital therapeutics are readily available for immediate veterinary use. Their therapies promote tissue regeneration, enhance overall physical condition, and facilitate faster healing in animals, addressing a range of clinical needs effectively.

Antibiotic Adjuvant, Inc. is a healthcare technology company based in Gainesville, Florida, founded in 2014. It specializes in developing decision support software aimed at improving antibiotic usage within healthcare facilities. The company's flagship product, SmartSteward, is designed to monitor and reduce infections and antibiotic resistance. It provides a suite of tools and educational resources tailored for healthcare administrators, physicians, and nurses. Administrators benefit from tools that optimize antibiotic use in real-time, while doctors receive pertinent information for effective prescribing. Nurses are equipped with surveillance tools for infection reporting and diagnosis. This innovative system addresses the complexities of antibiotic prescriptions in hospitals, aiming to enhance precision medicine for infectious diseases and promote automated resistance control.